Company / Accounts Receivable
Adaptimmune Therapeutics PLC Accounts Receivable History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$1.5M
FY2024
5-year range
$139.0K / $7.4M
FY2020-FY2024
Trend
+77.1%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable has fluctuated over the past 8 years, ranging from $139,000 in FY2020 to $7M in FY2022.
Based on SEC 10-K filings.
$1M in FY2024 with a 3-year CAGR of +24.6%.
Declined from $7M to $1M over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +24.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +24.6%, indicating consistent growth.
- In FY2024, accounts receivable increased 77.1% year-over-year.
- Peak accounts receivable was recorded in FY2022.
- Lowest accounts receivable in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score -3.53 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $1.5M | +77.1% |
| FY2023 | $821.0K | -89.0% |
| FY2022 | $7.4M | +888.7% |
| FY2021 | $752.0K | +441.0% |
| FY2020 | $139.0K | - |
| FY2019 | - | - |
| FY2018 | $192.0K | -6.8% |
| FY2017 | $206.0K | -86.1% |
| FY2016 | $1.5M | - |
As of FY2024 · SEC 10-K · Updated Jun 29, 2026